trial

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCTId NCT07184619
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 400 (estimated)
Sponsored by Newron Pharmaceuticals SPA
Primary completion 2026-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
400 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-01-23
Primary completion
2026-12-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Evenamide

Sponsors

Newron Pharmaceuticals SPALead Sponsor

Investigators

1
Ravi Anand, MDStudy Director

Sites

10 total
Los Angeles, United StatesMiami, United StatesAtlanta, United StatesBaltimore, United StatesNew York, United StatesVijayawada, IndiaMumbai, IndiaMadurai, IndiaLucknow, IndiaKolkata, India

Linked catalysts

1
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subje — primary completion2026-12-31

Facts & assertions

4 sourced
Enrollment
400
Phase
PHASE3
Primary Completion Date
2026-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Evenamide
drug
lead_sponsor
Newron Pharmaceuticals SPA
company
indication
Schizophrenia, Treatment-Resistant
indication
Schizophrenia
indication
Treatment-resistant Schizophrenia
indication
investigator
Ravi Anand, MD
person